Longevity medicine is attracting extraordinary interest—from patients, investors, researchers and clinicians. Yet one practical question has received far less attention: are doctors being trained to navigate it responsibly?
A new peer-reviewed study, published in JMIR Medical Education, offers an early answer. The survey examined physicians who had completed accredited online courses in healthy longevity medicine, a field that aims to apply insights from the biology of ageing to preventive and clinical care.
Among 113 responding physicians from 42 nationalities, 96.5% said they felt more confident in their knowledge after the course. More than half reported integrating healthy longevity principles into routine patient assessments, while 80.5% said they were having healthspan-focused conversations with patients more often.
At first glance, that may sound like a decisive endorsement of longevity medicine. It is better understood as something more measured—and arguably more important: a sign that clinicians want structured, evidence-aware ways to engage with the science of ageing.
Education may be the missing bridge
Geroscience has made striking progress in recent years. Researchers are studying the biological processes that contribute to ageing and age-related disease, while new tools—from biological-age measurements to AI-supported research—are entering the conversation.
But clinical practice has not moved at the same speed.
Doctors are often confronted with patients asking about biological-age tests, supplements, fasting protocols, hormone therapies, personalised prevention plans or the latest “anti-ageing” intervention. The difficulty is that scientific promise, commercial enthusiasm and proven clinical benefit do not always align.
The study’s central value lies in identifying education as a possible bridge. A clinician who understands the limits of a biomarker, the quality of available evidence and the difference between prevention and speculation is better equipped to help patients make informed choices.
That matters because the alternative is not necessarily clinical caution. It can be confusion, fragmented advice or a vacuum filled by marketing.
What the study actually shows
The research surveyed doctors who had completed online healthy longevity medicine courses between 2023 and early 2024. The programme lasted approximately two hours and forty minutes and covered core concepts in the biology of ageing, diagnostics, biomarkers, clinical frameworks and emerging interventions.
Participants reported higher confidence, more frequent longevity-related patient discussions and greater use of relevant testing. Physicians in specialised care reported particularly strong gains in confidence, while primary and preventive-care doctors reported greater integration of healthy longevity principles into routine assessments.
These results are encouraging—but they should not be overstated.
The study does not show that the course improved patient outcomes. It does not establish that biological-age tests change clinical decision-making for the better. Nor does it prove that any particular longevity intervention extends healthspan.
It measures self-reported confidence and intended or reported changes in practice. That is useful information, especially in an emerging field, but it is not the same as evidence of clinical effectiveness.
The need for standards, not hype
The authors themselves are clear about the limitations. The survey had a 19.2% response rate among eligible physicians, meaning those who participated may have been especially interested in the field. The findings may also be influenced by recall and social-desirability bias. And because the study is cross-sectional, it cannot establish cause and effect.
There is also a transparency point worth noting. Several authors are volunteers with the Longevity Education Hub, the non-profit platform whose courses were evaluated. That affiliation is disclosed in the paper. It does not invalidate the work, but it reinforces the need for independent replication and longer-term research.
This is precisely where the future of longevity medicine will be decided.
The field needs clearer clinical standards, better outcome data, independent education, and honest communication about uncertainty. Biomarkers of ageing may be valuable research and monitoring tools, but they are not yet universal decision-makers for individual patients. Novel therapies may be scientifically compelling, but compelling is not the same as clinically proven.
A responsible longevity practice should be built around the fundamentals that already have strong evidence: prevention, exercise, nutrition, sleep, metabolic health, cardiovascular risk reduction, vaccination, early detection where appropriate, and personalised care grounded in a patient’s actual needs.
A promising beginning
The most interesting finding may not be the high confidence scores. It is the underlying demand.
Nearly all respondents supported formal accreditation for physicians and clinics working in healthy longevity medicine. That suggests clinicians recognise both the opportunity and the responsibility. If longevity medicine is to become part of mainstream care, it cannot rely on charismatic claims or isolated protocols. It needs training pathways that teach critical appraisal as rigorously as innovation.
The study is therefore not a declaration that longevity medicine has arrived. It is evidence that medicine is beginning to prepare for its arrival.
For patients, that distinction is crucial. The goal should not be to chase every new test or intervention. It should be to find clinicians who can separate meaningful prevention from premature promise—and who understand that extending healthspan begins with evidence, not excitement.